AIFinancial Timesabout 2 hours ago
Pathos AI Licenses JSKN016 from Alphamab Oncology
1 min read
Pathos AI entered a global licensing agreement with Alphamab Oncology for JSKN016, a first-in-class TROP2/HER3 bispecific ADC. The deal grants Pathos AI worldwide rights to develop and commercialize the candidate. Financial terms were not disclosed.
Level
Hype check
Tap to vote and see what everyone thinks.
Summary by ByteBrief
